Progress towards recombinant anti-infective antibodies
The global market for monoclonal antibody therapeutics reached a total of $11.2 billion in 2004, with an impressive 42% growth rate over the previous five years and is expected to reach approximately $34 billion by 2010. Coupled with this growth are stream-lined product development, production scale...
Saved in:
| Published in | Recent patents on anti-infective drug discovery Vol. 4; no. 1; p. 1 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
01.01.2009
|
| Subjects | |
| Online Access | Get more information |
Cover
Loading…
| Abstract | The global market for monoclonal antibody therapeutics reached a total of $11.2 billion in 2004, with an impressive 42% growth rate over the previous five years and is expected to reach approximately $34 billion by 2010. Coupled with this growth are stream-lined product development, production scale-up and regulatory approval processes for the highly conserved antibody structure. While only one of the 21 current FDA-approved antibodies, and one of the 38 products in advanced clinical trials target infectious diseases, there is increasing academic, government and commercial interest in this area. Synagis, an antibody neutralizing respiratory syncitial virus (RSV), garnered impressive sales of $1.1 billion in 2006 in spite of its high cost and undocumented effects on viral titres in human patients. The success of anti-RSV passive immunization has motivated the continued development of anti-infectives to treat a number of other infectious diseases, including those mediated by viruses, toxins and bacterial/ fungal cells. Concurrently, advances in antibody technology suggest that cocktails of several monoclonal antibodies with unique epitope specificity or single monoclonal antibodies with broad serotype specificity may be the most successful format. Recent patents and patent applications in these areas will be discussed as predictors of future anti-infective therapeutics. |
|---|---|
| AbstractList | The global market for monoclonal antibody therapeutics reached a total of $11.2 billion in 2004, with an impressive 42% growth rate over the previous five years and is expected to reach approximately $34 billion by 2010. Coupled with this growth are stream-lined product development, production scale-up and regulatory approval processes for the highly conserved antibody structure. While only one of the 21 current FDA-approved antibodies, and one of the 38 products in advanced clinical trials target infectious diseases, there is increasing academic, government and commercial interest in this area. Synagis, an antibody neutralizing respiratory syncitial virus (RSV), garnered impressive sales of $1.1 billion in 2006 in spite of its high cost and undocumented effects on viral titres in human patients. The success of anti-RSV passive immunization has motivated the continued development of anti-infectives to treat a number of other infectious diseases, including those mediated by viruses, toxins and bacterial/ fungal cells. Concurrently, advances in antibody technology suggest that cocktails of several monoclonal antibodies with unique epitope specificity or single monoclonal antibodies with broad serotype specificity may be the most successful format. Recent patents and patent applications in these areas will be discussed as predictors of future anti-infective therapeutics. |
| Author | Maynard, Jennifer A Sutherland, Jamie N Pai, Jennifer C |
| Author_xml | – sequence: 1 givenname: Jennifer C surname: Pai fullname: Pai, Jennifer C organization: Department of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA – sequence: 2 givenname: Jamie N surname: Sutherland fullname: Sutherland, Jamie N – sequence: 3 givenname: Jennifer A surname: Maynard fullname: Maynard, Jennifer A |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19149692$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1j8tKBDEQRbMYcR76Ay6kf6A1laRTqaUMvmBAFwruhk5SLRG7e0haxb93fC0uh3sWF-5SzIZxYCFOQJ4pQHMODRpHIAkdKm010EwsvmW9t09zsSzlRUrTSFSHYg4EhiyphbD3eXzOXEo1jR9tjqXKHMbep6EdpmqfVKeh4zCld_6pfoyJy5E46NrXwsd_XInHq8uH9U29ubu-XV9sat9oTbXtTFDYkkcmptAE7wwgu-C0UwGkjD40CCqiNSg7qToTUROwBAvWsFqJ09_d3ZvvOW53OfVt_tz-H1Bfrt9HyA |
| CitedBy_id | crossref_primary_10_1016_j_vaccine_2009_09_105 crossref_primary_10_2217_fmb_11_32 crossref_primary_10_1146_annurev_chembioeng_073009_100952 crossref_primary_10_3390_ph3051561 crossref_primary_10_1016_j_nbt_2011_03_018 crossref_primary_10_3390_vaccines10111789 crossref_primary_10_1128_AAC_00279_17 crossref_primary_10_2217_imt_09_76 crossref_primary_10_1016_j_jmgm_2014_07_005 crossref_primary_10_1371_journal_pone_0013253 crossref_primary_10_1002_biot_200900195 crossref_primary_10_1128_AAC_00607_16 crossref_primary_10_1016_j_antiviral_2012_11_003 crossref_primary_10_1155_2015_347903 crossref_primary_10_1016_j_compbiolchem_2016_08_004 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM |
| DOI | 10.2174/157489109787236319 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
| DatabaseTitleList | MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| ExternalDocumentID | 19149692 |
| Genre | Review Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R21 AI066239-02 – fundername: NIAID NIH HHS grantid: AI066239 – fundername: NIAID NIH HHS grantid: R21 AI066239 |
| GroupedDBID | --- .5. 0R~ 123 29P 4.4 AAEGP ABJNI ABKHR ACGFS ACITR AGJNZ ALMA_UNASSIGNED_HOLDINGS ANTIV CGR CS3 CUY CVF EBS ECM EIF EJD F5P GH2 HZ~ IPNFZ KCGFV NPM O9- OVD RIG TEORI |
| ID | FETCH-LOGICAL-b5339-6f4c27a9b7e9e9c5cb8417e8c8382c100dbc5712d76470f02f4d7391e016164e2 |
| ISSN | 1574-891X |
| IngestDate | Thu May 23 23:13:58 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Issue | 1 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-b5339-6f4c27a9b7e9e9c5cb8417e8c8382c100dbc5712d76470f02f4d7391e016164e2 |
| OpenAccessLink | https://europepmc.org/articles/pmc2800955?pdf=render |
| PMID | 19149692 |
| ParticipantIDs | pubmed_primary_19149692 |
| PublicationCentury | 2000 |
| PublicationDate | 2009-Jan |
| PublicationDateYYYYMMDD | 2009-01-01 |
| PublicationDate_xml | – month: 01 year: 2009 text: 2009-Jan |
| PublicationDecade | 2000 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Recent patents on anti-infective drug discovery |
| PublicationTitleAlternate | Recent Pat Antiinfect Drug Discov |
| PublicationYear | 2009 |
| References | 15857975 - J Virol. 2005 May;79(10):5900-6 12177434 - Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11346-50 18066039 - Nat Biotechnol. 2007 Dec;25(12):1421-34 11988060 - JAMA. 2002 May 8;287(18):2391-405 18989460 - PLoS Pathog. 2008 Nov;4(11):e1000197 15809906 - J Infect Dis. 2005 May 1;191(9):1472-7 11796590 - Infect Immun. 2002 Feb;70(2):612-9 15123813 - Proc Natl Acad Sci U S A. 2004 May 11;101(19):7270-4 18574240 - J Biol Chem. 2008 Aug 29;283(35):24089-102 16966409 - Infect Immun. 2006 Nov;74(11):6339-47 2508701 - Curr Opin Immunol. 1989 Feb;1(3):462-6 17500025 - Curr Opin Chem Biol. 2007 Jun;11(3):306-15 11119555 - Infect Immun. 2001 Jan;69(1):570-4 12930899 - Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10942-7 17030576 - Infect Immun. 2006 Dec;74(12):6992-8 2426862 - Virology. 1986 Sep;153(2):168-78 15210961 - Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9 16140750 - J Virol. 2005 Sep;79(18):11724-33 16022791 - Emerg Infect Dis. 2005 Jul;11(7):1108-11 18706916 - J Mol Biol. 2008 Oct 24;382(5):1211-27 12784377 - Proteins. 2003 Jul 1;52(1):118-22 16619152 - Clin Infect Dis. 2006 May 15;42(10):1404-13 18304641 - Mol Immunol. 2008 May;45(9):2710-4 10073283 - Annu Rev Med. 1999;50:355-67 10627493 - Clin Microbiol Rev. 2000 Jan;13(1):83-121, table of contents 15852016 - Nat Med. 2005 May;11(5):522-30 2474500 - Infect Immun. 1989 Sep;57(9):2660-5 16570858 - Curr Top Microbiol Immunol. 2006;303:97-120 18586298 - Virology. 2008 Sep 1;378(2):205-13 17893153 - Antimicrob Agents Chemother. 2007 Dec;51(12):4249-54 16322603 - N Engl J Med. 2005 Dec 8;353(23):2433-41 18005691 - Cell Host Microbe. 2007 Apr 19;1(2):135-45 18694970 - Infect Immun. 2008 Oct;76(10):4469-78 15683685 - Burns. 2005 Mar;31(2):153-8 17597458 - J Infect Dis. 2007 Aug 1;196(3):435-40 18410248 - Annu Rev Biochem. 2008;77:363-82 3898484 - Trans R Soc Trop Med Hyg. 1985;79(3):380-4 2465274 - Infect Immun. 1989 Mar;57(3):944-50 17427229 - Proteins. 2007 Jul 1;68(1):294-304 17500026 - Curr Opin Chem Biol. 2007 Jun;11(3):347-54 19029986 - Nat Med. 2008 Dec;14(12):1357-62 15844622 - Curr Opin Mol Ther. 2005 Apr;7(2):144-50 17173035 - Nat Biotechnol. 2007 Jan;25(1):107-16 18522504 - J Infect Dis. 2008 Aug 1;198(3):344-8 15937757 - Clin Infect Dis. 2005 Jul 1;41(1):12-20 17310321 - Biotechnol Lett. 2007 Jun;29(6):845-52 6464130 - Trans R Soc Trop Med Hyg. 1984;78(3):319-24 18421377 - PLoS Pathog. 2008 Apr;4(4):e1000047 15907931 - J Mol Biol. 2005 Jul 1;350(1):126-44 2466764 - Hybridoma. 1989 Feb;8(1):37-51 15972493 - Infect Immun. 2005 Jul;73(7):4054-61 15197275 - Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9193-8 18264102 - Nat Immunol. 2008 Mar;9(3):301-9 2777380 - Infect Immun. 1989 Oct;57(10):3214-20 16436502 - Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1882-7 16596663 - Biotechnol Bioeng. 2006 Jun 5;94(2):396-405 18447660 - Pharmacotherapy. 2008 May;28(5):614-45 1376367 - J Virol. 1992 Jul;66(7):4252-7 16796401 - PLoS Med. 2006 Jul;3(7):e237 17581986 - J Virol. 2007 Sep;81(17):8989-95 16453264 - J Infect Dis. 2006 Mar 1;193(5):685-92 12761090 - Infect Immun. 2003 Jun;71(6):3125-30 17719934 - J Pediatr. 2007 Sep;151(3):260-5, 265.e1 1698179 - Infect Immun. 1990 Oct;58(10):3369-74 17160047 - Nat Biotechnol. 2006 Dec;24(12):1491-3 2471267 - Science. 1989 Jun 2;244(4908):1081-5 1718872 - Infect Immun. 1991 Nov;59(11):4249-51 6098581 - J Biol Stand. 1984 Oct;12(4):353-65 15498605 - Antiviral Res. 2004 Nov;64(2):103-11 17785821 - J Immunol. 2007 Sep 15;179(6):3841-50 14872095 - Sci STKE. 2004 Feb 10;2004(219):pl2 18246521 - Curr Opin Investig Drugs. 2008 Feb;9(2):184-8 1778307 - Dev Biol Stand. 1991;73:133-41 16954221 - J Biol Chem. 2006 Nov 10;281(45):34610-6 17515896 - Nat Med. 2007 Jun;13(6):725-9 18199635 - J Virol. 2008 Apr;82(7):3220-35 18656541 - Curr Opin Immunol. 2008 Aug;20(4):460-70 15642942 - Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):797-801 16186811 - Nat Biotechnol. 2005 Oct;23(10):1283-8 17005807 - Antimicrob Agents Chemother. 2006 Oct;50(10):3289-96 17195712 - Pediatr Infect Dis J. 2007 Jan;26(1):79-81 2474891 - Virology. 1989 Aug;171(2):417-26 16382463 - Liver Transpl. 2006 Jan;12(1):124-33 11209178 - JAMA. 2001 Feb 28;285(8):1059-70 6715049 - Infect Immun. 1984 May;44(2):528-33 16537476 - Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4005-10 16306604 - J Virol. 2005 Dec;79(24):15331-41 15780806 - J Clin Virol. 2005 Apr;32(4):286-8 18221173 - Recent Pat Antiinfect Drug Discov. 2007 Nov;2(3):171-7 17059824 - J Mol Biol. 2007 Jan 5;365(1):196-210 1682643 - Lancet. 1991 Nov 16;338(8777):1230-3 17116920 - Ann Intern Med. 2006 Nov 21;145(10):758-64 17362988 - J Mol Biol. 2007 May 4;368(3):652-65 12213339 - J Immunol Methods. 2002 Oct 1;268(1):21-8 4414805 - Immunochemistry. 1974 May;11(5):223-5 8470429 - Vaccine. 1993;11(4):445-8 16598296 - J Perinatol. 2006 May;26(5):290-5 15027061 - Mov Disord. 2004 Mar;19 Suppl 8:S101-8 18442991 - Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W233-8 17671962 - Proteins. 2008 Jan 1;70(1):218-30 6207108 - Infect Immun. 1984 Oct;46(1):195-201 15372080 - Nat Rev Microbiol. 2004 Sep;2(9):695-703 10391844 - Clin Diagn Lab Immunol. 1999 Jul;6(4):464-70 18480433 - J Virol. 2008 Jul;82(14):6869-79 12042864 - Nat Biotechnol. 2002 Jun;20(6):597-601 15855500 - Antimicrob Agents Chemother. 2005 May;49(5):1808-12 16809304 - J Virol. 2006 Jul;80(14):6982-92 11698464 - J Immunol. 2001 Nov 15;167(10):5880-6 18066033 - Nat Biotechnol. 2007 Dec;25(12):1390-3 18452606 - Virol J. 2008;5:56 8326138 - J Immunol. 1993 Jul 1;151(1):466-72 17301098 - Eur Respir J. 2007 May;29(5):965-8 18066027 - Nat Biotechnol. 2007 Dec;25(12):1369-72 17939955 - Arch Pediatr. 2007 Sep;14 Suppl 1:S31-4 10908667 - Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):8950-4 14714897 - Adv Exp Med Biol. 2003;535:205-18 14985706 - Nat Immunol. 2004 Mar;5(3):233-6 18162943 - Pediatr Infect Dis J. 2008 Jan;27(1):69-70 10884621 - Microbes Infect. 2000 May;2(6):701-8 16870768 - Antimicrob Agents Chemother. 2006 Aug;50(8):2751-5 15220038 - Lancet. 2004 Jun 26;363(9427):2139-41 15489355 - Clin Microbiol Rev. 2004 Oct;17(4):926-41, table of contents 590997 - Immunology. 1977 Dec;33(6):807-15 18837784 - Immunol Rev. 2008 Oct;225:212-25 11756984 - J Infect Dis. 2002 Jan 1;185(1):74-84 16518829 - Rev Med Virol. 2006 Mar-Apr;16(2):117-31 2471803 - J Gen Virol. 1989 May;70 ( Pt 5):1125-32 17961824 - Chem Biol. 2007 Oct;14(10):1119-27 19079604 - PLoS One. 2008;3(12):e3942 18957538 - Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17121-6 10816464 - Infect Immun. 2000 Jun;68(6):3200-9 10391179 - Pediatr Infect Dis J. 1999 Jun;18(6):505-11 1708105 - Mol Immunol. 1991 Mar;28(3):247-50 17392523 - Mol Pharmacol. 2007 Jul;72(1):18-28 12089663 - J Infect Dis. 2002 Jul 1;186(1):64-73 15295704 - J Infect Dis. 2004 Sep 1;190(5):975-8 |
| References_xml | |
| SSID | ssj0045072 |
| Score | 1.5788933 |
| SecondaryResourceType | review_article |
| Snippet | The global market for monoclonal antibody therapeutics reached a total of $11.2 billion in 2004, with an impressive 42% growth rate over the previous five... |
| SourceID | pubmed |
| SourceType | Index Database |
| StartPage | 1 |
| SubjectTerms | Anti-Infective Agents - pharmacology Antibodies - pharmacology Epitope Mapping Protein Engineering Recombinant Proteins - pharmacology |
| Title | Progress towards recombinant anti-infective antibodies |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/19149692 |
| Volume | 4 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwELagXLggKOXdygfEpaSNEye2j6hqhZBAe1gkbii2JxUHFgQL0vLrmbHzWqBVy2Gj3VjJZjOzk3l88w1j-1nhjU-hSoTIHQYoqU60ppGANkfnwFV1WQWA7Fl5fC5PLopBoT10l0ztN_f0Zl_Je6SK-1Cu1CX7H5LtToo78D3KF7coYdz-k4xHBK4iUzUN4FeqAODX2ABu-Yqvq6TBWj1C-GhvOsxgy8kNhM4kdtXQ6RagyXOH-buH31TFcQT17NLvozjEuoXGDFKtD23_cAPBvYK-2HNazSZVhNJ3Rx7NpR3MIO3QWEolE23CvJvOlMpXGhPNonjLWFMwRHmDgghwqBCuVZaXebSgA-ndXgfxERGdKePgvL-vviDQbpcW2aLSZArPKKETH9YS3eFQEG9_Teyrokv7_vrCAsNsPNmLKCR4I-NVttKEEfwo6sQaW4DJR3Ywijzks0M-7tvq7g_5AR_1DOWzdVa2isMbxeEDxeHzGsB7xfnEzn_9HP84TpoBGolFL94kZS1dpipjFRgwrnBWS6FAO53rzIk09dYVSmRelVKldZrV0qvcCKA4oJSQbbAPk5sJbDEO1hQZgAaRC-mtrCqlfV5jaAZEuOS32Wa8H5e3kSXlsr1TO39c2WXLvWbtsaUa_5bwGX28qf0SpPQMC0VPYw |
| link.rule.ids | 783 |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Progress+towards+recombinant+anti-infective+antibodies&rft.jtitle=Recent+patents+on+anti-infective+drug+discovery&rft.au=Pai%2C+Jennifer+C&rft.au=Sutherland%2C+Jamie+N&rft.au=Maynard%2C+Jennifer+A&rft.date=2009-01-01&rft.issn=1574-891X&rft.volume=4&rft.issue=1&rft.spage=1&rft_id=info:doi/10.2174%2F157489109787236319&rft_id=info%3Apmid%2F19149692&rft_id=info%3Apmid%2F19149692&rft.externalDocID=19149692 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1574-891X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1574-891X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1574-891X&client=summon |